Production, novel assay development and clinical applications of monoclonal antibodies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 258-267

  Chiarella, Pieranna ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cancer; Diagnosis; Hybridoma technology; Immunoconjugate; Microarray; Monoclonal antibody

Indexed keywords

BCR ABL PROTEIN; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY LABELING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYBRIDOMA; IMMUNOASSAY; MICROARRAY ANALYSIS; NONHUMAN; PATENT; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYBRIDOMAS; MICE; MICROARRAY ANALYSIS; NEOPLASMS; PATENTS AS TOPIC;

EID: 79954512464     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328549     Document Type: Article

References (101)

1. Phyzicky E, Bastiaens PI, Zhu H, Sneyder M, Fields S. Protein analysis on a proteomic scale. Nature 2003; 422: 208-15.
2. Hanash S. Disease proteomics. Nature 2003; 422: 226-32.
3. Skerra A. Alternative non antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18: 295-304.
4. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-56.
5. Ning Y, Wang Y, Li Y, Hong Y, Peng D, Liu Y, et al. An alternative strategy for high throughput generation and characterization of monoclonal antibodies against human plasma proteins using fractionated native proteins as immunogens. Proteomics 2006; 6: 438-48.
6. Holliger P, Hudsnon PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
7. Chambers RS, Johnston SA. High level generation of polyclonal antibodies by genetic immunization. Nat Biotechnol 2003; 21: 1088-92.
8. Berry JD, Licea A, Popkov M, Cortez X, Fuller R, Elia M, et al. Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 2003; 22: 23-31.
9. Kelley, B. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Prog 2007; 23: 995-1008.
10. Bradbury A, Velappan N, Verzillo V, Ovecka M, Chasteen L, Sblattero D, et al. Antibodies in proteomics I: Generating antibodies. Trends Biotechnol 2003; 21: 275-81.
11. Birch JR, Racher J. Antibody production. Adv Drug Deliv Rev 2006; 58: 671-85.
12. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
13. Bradbury A, Velappan N, Verzillo V, Ovecka M, Chasteen L, Sblattero D, et al. Antibodies in proteomics II: Screening, highthroughput characterization and downstream applications. Trends Biotechnol 2003; 21: 312-7.
14. Schwenk JM, Lindberg J, Sundberg M, Uhlèn M, Nilsson P. Determination of binding specificities in high-multiplexed bead based-assays for antibody proteomics. Mol Cell Proteomics 2007; 6: 125-32.
15. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, et al. Towards a human proteome atlas: Highthroughput generation of mono-specific antibodies for tissue profiling. Proteomics 2005; 5: 4327-37.
16. Chapman T. Lab automation and robotics: Automation on the move. Nature 2003; 421: 661-6.
17. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 1975; 256: 495-7.
18. Kilpatrick KE, Kerner S, Dixon EP, Hutchins JT, Parham JH, Condreay JP, et al. In vivo expression of a GST-fusion protein mediates the rapid generation of affinity matured monoclonal antibodies using DNA-based immunizations. Hybrid Hybridomics 2002; 21: 237-43.
19. Chiarella P, Edelmann B, Fazio VM, Sawyer AM, de Marco A. Antigenic features of protein carriers commonly used in immunisation trials. Biotechnol Lett 2010; 32: 1215-21.
20. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines 2007; 6: 673-84.
21. de Marco A. Protocol for preparing proteins with improved solubility by co-expressing with molecular chaperones in Escherichia coli. Nat Protoc 2007; 2: 2632-9.
22. Ny Y, Ma K, Ni J, Zheng X, Wang Y, Xiong S. A rapid and simple approach to preparation of monoclonal antibody based on DNA immunization. Cell Mol Immunol 2004; 1: 295-9.
23. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokineexpressing plasmids. J Immunol 1997; 158: 1231-7.
24. Chiarella P, Massi E, De Robertis M, Signori E, Fazio VM. Adjuvants in vaccines and for immunisation: Current trends. Expert Opin Biol Ther 2007; 7: 1551-62.
25. Maue AC, Eaton SM, Lanthier PA, Sweet KB, Blumerman SL, Haynes L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J Immunol 2009; 182: 6129-35.
26. Sawyer, A., De Masi, F. Methods for producing monoclonal antibodies. WO03089471 (2003).
27. De Masi F, Chiarella P, Wilhelm H, Massimi M, Bullard B, Ansorge W, et al. High throughput production of mouse monoclonal antibodies using antigen microarrays. Proteomics 2005; 5: 4070-81.
28. Bystryn JC, Jacobsen JS, Liu P, Heaney-Kieras J. Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. Hybridoma 1982; 1: 465-72.
29. Sehgal D, Johnson G, Wu TT, Mage RG. Generation of the primary antibody repertoire in rabbits: Expression of a diverse set of Igk-V genes may compensate for limited combinatorial diversity at the heavy chain locus. Immunogenetics 1999; 50: 31-42.
30. Raybould TJ, Takahashi M. Production of stable rabbit-mouse hybridomas that secrete rabbit mAb of defined specificity. Science 1988; 240: 1788-90.
31. Pytela, R., Weimin, Z., Yaohuang, K., Qian, Q., Au, H.C. Fusion partner for production of monoclonal rabbit antibodies. US20090142807 (2009).
32. Pasqualini, R., Arap, W. Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations. WO2004092220 (2004).
33. Pasqualini R, Arap W. Hybridoma-free generation of monoclonal antibodies. Proc Natl Acad Sci USA 2004; 101: 257-9.
34. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871-5.
35. Li J, Sai T, Berger M, Chao Q, Davidson D, Deshmukh G, et al. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc Natl Acad Sci USA 2006; 103: 3557-62.
36. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-56.
37. Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999; 162: 3663-71.
38. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-5.
39. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
40. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-55.
41. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23: 1117-25.
42. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
43. Svehag SE, Blot B, Seligmann M. Ultrastructure of papain and pepsin digestion of human IgM globulins. J Exp Med 1969; 130: 691-705.
44. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246: 1275-81.
45. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63.
46. Johnson, L.S., Hiang, L. Covalent diabodies and uses thereof. WO2010080538 (2010).
47. Stavenhagen, J. Engineering Fc antibody regions to confer effector function. US20100196362 (2010).
48. Haab BB. Methods and applications of antibody microarrays in cancer research. Proteomics 2003; 3: 2116-22.
49. Wingren C, Borrebaeck CAK. Antibody microarrays: Current status and key technological advances. OMICS 2006; 10: 411-27.
50. Kim, H., Dombkowski, A.A., Novak, R.F., Haab, B.B. Chip production, hybridization and data interpretation for antibody and protein microarrays. WO2005090546 (2005).
51. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007; 6: 25.
52. Garcia-Foncillas J, Bandres E, Zarate N, Remirez N. Proteomic analysis in cancer research: potential application in clinical use. Clin Transl Oncol 2006; 8: 250-61.
53. Baptista, C.S., Best, L., Munroe, J.D. Monoclonal antibody microarray. WO2007130549 (2007).
54. Tavitian, B., Zueva, E. Specific aptamers generated for suppression of cell migration and invasion by cancer cells, methods of selection for such aptamers and their usage. WO2009090554 (2009).
55. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Invest Drugs 2009; 10: 1212-24.
56. Ramaswamy A, Lin E, Chen I, Mitra R, Morrisett J, Coombes K, et al. Application of protein lysate microarrays to molecular marker verification and quantification. Proteome Sci 2005; 3: 9.
57. Cretich M, Damin F, Pirri G, Chiari M. Protein and peptide arrays: Recent trends and new directions. Biomol Eng 2006; 23: 77-88.
58. Haab B, Dunham M, Brown P. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001; 2: 1-13.
59. Servoss SL, Gonzalez R, Varnum S, Zangar RC. High-throughput analysis of serum antigens using sandwich ELISAs on microarrays. Methods Mol Biol 2009; 520: 143-50.
60. Ezaki, T. Antibody testing method and antigen microarray. EP1310794 (2003).
61. Van Meter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF III. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007; 7: 625-33.
62. Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 2008; 3: 1796-808.
63. Korf U, Derdak S, Tresch A, Henjes F, Schumacher S, Schmidt C, et al. Quantitative protein microarrays for time-resolved measurements of protein phosphorylation. Proteomics 2008; 8: 4603-12.
64. Jona G, Snyder M. Recent developments in analytical and functional protein microarrays. Curr Opin Mol Ther 2003; 5: 271-77.
65. Takacs, L., Guttrman, A., Hancock, W.S., Karger, B. L., Duval, M., Berna, P. Monoclonal antibody based biomarker discovery and development platform. WO2005077106 (2005).
66. Takacs, L., Guttrman, A., Hancock, W.S., Karger, B.L., Duval, M., Berna, P. Monoclonal antibody based biomarker discovery and development platform. US20070172887 (2007).
67. Wang D, Hincapie M, Guergova-Kuras M, Kadas J, Takacs L, Karge BL. Antigen identification and characterization of lung cancer specific monoclonal antibodies produced by mAb proteomics. J Proteome Res 2010; 9: 1834-42.
68. Baccarani M, Pane F, Saglio G. Monitoring treatment for chronic myeloid leukemia. Haematologica 2008; 93: 161-6.
69. Quintás-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-30.
70. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, et al. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res 2008; 32: 936-43.
71. Van Denderen J, Ten Hachen P, Berendes P, Zegers N, Boersma W, Grosveld G, et al. Recognition of the ALL-specific BCR-ABL junction in P190 BCR-ABL by monoclonal antibody ER-FP1. Leukemia 1994; 8: 1503-9.
72. Van Denderen J, Hermans J, Meeuwsen T, Troelstra C, Zegers N, Boersma W, et al. Antibody recognition of the tumor specific BCR-ABL joining region in chronic myeloid leukemia. J Exp Med 1989; 169: 87-9.
73. Wetzel, R., Brown, C. Antibodies specific for BCR/ABL fusion protein and uses thereof. WO2005102938 (2005).
74. Berendes, P.B., Veenman, J.N., Van Denderen, A.C., Van Ewijk, W. Recognition of tumour-specific products in cancer. US6610498 (2003).
75. Van Dongen, J.J.M., Van der Velden, V.H.J., Berendes, P.B., Van Denderen, A.C. Recognition of tumour-specific products in cancer. WO02054074 (2002).
76. Weerkamp F, Dekking E, Ng YY, van der Velden VH, Wai H, Böttcher S, et al. Flow cytometric imunobead assay for the detection of BCRABL fusion proteins in leukemia patients. Leukemia 2009; 23: 1106-17.
77. Sang BC, Shi L, Dias P, Liu L, Wei J, Wang ZX, et al. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: Characterization and diagnostic utility. Blood 1997; 89: 2909-14.
78. Gruenwald, S., Sang, B.C., Monell C. E2A/pbx1 fusion protein specific monoclonal antibodies. US5858682 (1999).
79. Goldenberg, D.M. Humanized L243 Antibodies US20100196267 (2010).
80. Goldenberg, D.M. Humanized anti-HLA-DR antibodies US20100196266 (2010).
81. Hudelist G, Pacher-Zavisin M, Singer CF, Holper T, Kubista E, Schreiber M, et al. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 2004; 86: 281-91.
82. Borrebaeck, A.K., Wingren, L.B.C. Diagnostic methods and arrays for using the same. WO2009068857 (2009).
83. Dai, H., He, Y., Mao, M., Fine, B., Van't Veer, L.J., Van de Vijver, M.J. Prognosis of breast cancer patients. US20090239214 (2009).
84. Dai, H., He, Y., Linseley, P.S., Mao, M., Roberts, C.J., Van't Veer, L.J., Van de Vijver, M.J., Bernards, R., Hart, A.A.M. Diagnosis and prognosis of breast cancer patients. US20090157326 (2009).
85. Sahin, U., Tuereci, O., Koslowski, M., Mitnacht-Kraus, R. Monoclonal antibodies for treatment of cancer. WO2010031551 (2010).
86. Kufer P, Lutterbuse R, Baeuerlel PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22: 238-44.
87. Kufer, P., Berry, M., Baeuerle, P., Itin, C. Bispecific antibodies. WO2005061547 (2005).
88. Nielsen, U.B., Schoeberl, B.M. Bispecific binding agents for modulating biological activity. US20090246206 (2009).
89. Nielsen, U.B., Schoeberl, B.M. Bispecific binding agents for modulating biological activity. US20090181022 (2009).
90. Chames P, Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? Monoclonal Antibodies 2009; 1: 539-47.
91. Chiarella P, Massi E, De Robertis M, Fazio VM, Signori E. Recent advances in epitope design for immunotherapy of cancer. Recent Pat Anticancer Drug Discov 2009; 4: 227-40.
92. Korman, A.J., Selby, M.J., Wang, C., Srinivasan, M., Passmore, D.B., Huang, H., Chen, H. Human monoclonal antibodies to be programmed death ligand (PD-L1). US20090055944 (2009).
93. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
94. Cartilage, S. Antibodies to ERbB2. US20100158926 (2010).
95. Hudziak, R.M., Shepard, H.M., Ullrich, A., Fendly, B.M. Monoclonal antibodies directed to the Her2 receptor. US6399063 (2002).
96. Grompe, M., Streeter, P.R., Dorrell, C., Abraham, S.L., Lanxon-Cookson, K.M. Monoclonal antibodies and their use. US20090098140 (2009).
97. Bristol, A.J., Kantor, J.A. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers. US20090162931 (2009).
98. Sherman, M.A., Wu, A.M., Reiter, R.E. Humanized anti-prostate stem cell antigen monoclonal antibody. US20060269557 (2006).
99. Copley M. D, Edge, C.G., Emery, S.C. Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system. US20056903203 (2005).
100. World Intellectual Property Organization. Available at http://www.wipo.int/sme/en/documents/freedom_to_operate.html
101. Zou W. Immunosuppressive networks in the tumour microenvironment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.